Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study
<p><strong>Background:</strong> Fibroblast growth factor 23 (FGF-23) is associated with a range of cardiovascular and non-cardiovascular diseases in conventional epidemiological studies, but substantial residual confounding may exist. Mendelian randomization approaches can help con...
| Autors principals: | , , , , , , |
|---|---|
| Format: | Journal article |
| Idioma: | English |
| Publicat: |
American Society of Nephrology
2022
|